Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector.
The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver).
The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer.
Rezensionen / Stimmen
"...a helpful reference for researchers and medical professionals interested in epigenetics...contains many resources that may be useful for readers or guide them to technologies and areas of interest quickly. Score: 84 - 3 Stars" --Doody's
Reihe
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science Publishing Co Inc
Zielgruppe
Für Beruf und Forschung
Researchers in molecular biology, genetics, and clinical therapy who are interested in the role of epigenetics in cancer biology or those seeking novel means to treat cancer.
Produkt-Hinweis
Fadenheftung
Gewebe-Einband
Illustrationen
Maße
Höhe: 241 mm
Breite: 6 mm
Dicke: 43 mm
Gewicht
ISBN-13
978-0-12-800206-3 (9780128002063)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Steven Gray is a Senior Clinical Scientist and Adjunct Assistant Professor in the Thoracic Oncology Research Group, Trinity Centre for Health Sciences at St. James's Hospital, Dublin, Ireland.
Herausgeber*in
Senior Clinical Scientist and Adjunct Assistant Professor, Thoracic Oncology Research Group, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland
1. Introduction
2. DNA Methylation & Hydroxymethylation in Cancer
3. Writers, Readers, and Erasers of Epigenetic Marks
4. MicroRNAs and Cancer
5. Long Noncoding RNAs (lncRNAs) and Cancer
6. Ribosomal RNA Methylation and Cancer
7. Mining the Epigenetic Landscape: Surface Mining or Deep Underground
8. Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality
9. Epigenetic Therapy in Lung Cancer and Mesothelioma
10. Breast Cancer Epigenetics
11. Therapeutic Applications of the Prostate Cancer Epigenome
12. Liver Cancer (Hepatocellular Carcinoma)
13. Neuroblastoma
14. The Epigenetics of Medulloblastoma
15. Clinical Significance of Epigenetic Alterations in Glioblastoma
16. Esophageal Cancer
17. Nasopharyngeal Cancer
18. Nutritional Epigenetic Inhibitors in the Field of Cancer: New Avenues for Chemopreventive Approaches
19. Emerging Epigenetic Therapies - Lysine Methyltransferase/PRC Complex Inhibitors
20. Inhibitors of Jumonji C Domain Histone Demethylases
21. Emerging Epigenetic Therapies - Lysine Acetyltransferase Inhibitors
22. Emerging Epigenetic Therapies - Bromodomain Ligands
23. Clinical Trials
24. Genetic Intratumor Heterogeneity
25. Epigenetics Underpinning DNA Damage repair
26. Epigenetics of Cisplatin Resistance
27. Therapeutically Targeting Epigenetic Regulation of Cancer Stem Cells
28. Personalized Therapy - Chemosensitivity Testing
29. Personalized Therapy - Epigenetic Profiling as Predictors of Prognosis and Response
